# A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

> **NCT06916806** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 72 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Idiopathic Inflammatory Myopathies
- Rheumatoid Arthritis

## Interventions

- **DRUG:** AZD5492

## Key facts

- **NCT ID:** NCT06916806
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-05-05
- **Final completion:** 2027-09-15
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06916806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06916806, "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06916806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*